Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Excerpt from the Press Release:

BRISBANE, Calif. – August 10, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism Spectrum Phenotype in Mice, at the Society for Industrial Microbiology and Biotechnology Annual Meeting 2021 held from August 8-11, 2021 in Austin, Texas. Todd DeSantis, co-founder and Vice President, Informatics at Second Genome, will also present these data in an additional oral presentation session, New Modes of Natural Product Bioactivity, today at 10:00 a.m. CT.

Second Genome assembled the largest meta-cohort of ASD to date which includes both data from published studies as well as a large longitudinal study. The analysis identified secondary bile acid metabolism as being altered in ASD with two bile acids, Glycodeoxycholate (GDC) and Ursodeoxycholate (UDC), predicted to be reduced in children with ASD. Preclinical treatment in an animal model with these metabolites demonstrated increases in expression for genes related to neurotransmitter receptors as well as post synaptic signal transmission. Furthermore, analyses of ASD- relevant behavioral domains demonstrated increased habituation exploration and decreased anxiogenic behavior in animals treated with the metabolites.

Click the button below to read the entire Press Release:

Continue Reading The Press Release